QUAD Ventures

Rznomics is a biotechnology company founded by professor Lee Sung-wook's lab, focusing on the development of innovative gene therapy products aimed at treating liver cancer and other serious medical conditions. The company specializes in ribonucleic acid-based therapies that address significant unmet medical needs, particularly in the areas of cancer, degenerative neurological disorders, and hereditary diseases. By creating new biopharmaceuticals, Rznomics aims to provide medical practitioners with effective treatment options for challenging health issues, including various types of cancer and Alzheimer’s disease. The company has garnered recognition for its technological excellence, having been selected for the TIPS program, which highlights its commitment to advancing medical science.

NeogenTC is focused on developing innovative cancer therapies aimed at providing personalized treatment options for patients. The company utilizes a novel antigen discovery platform that enhances the accuracy of predictions in identifying suitable targets for therapy. This platform is integrated with a unique immune cell therapy technology that directly binds to actual immune cells, allowing for targeted treatment of solid tumors that are typically challenging to manage. By enhancing the effectiveness of immune T-cell therapies, NeogenTC seeks to improve outcomes for patients facing difficult-to-treat cancers.